Completed PHASE2 INTERVENTIONAL 1-arm NCT02449551

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Sponsor: Samsung Medical Center

Conditions Advanced Gastric Adenocarcinoma

Interventions Volitinib

Updated 11 times since 2017 Last updated: Jun 13, 2022 Started: Feb 10, 2016 Primary completion: Dec 30, 2020 Completion: Aug 27, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Advanced Gastric Adenocarcinoma and is currently completed. Samsung Medical Center leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Mar 2022 — Jul 2022 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 6 earlier versions

Jan 2021 — Mar 2022 [monthly]

Recruiting PHASE2
Feb 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Jun 2019 — Feb 2020 [monthly]

Recruiting PHASE2
Jun 2018 — Jun 2019 [monthly]

Recruiting PHASE2
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea